Ellipses Pharma’s EP0042 Granted Orphan Drug Designation by FDA for AML Treatment
Ellipses Pharma obtains Orphan Drug Designation (ODD) from the FDA for EP0042, a dual FLT-3 and Aurora kinase inhibitor, as a treatment for acute myeloid leukaemia (AML). This designation is granted t ...